for Thank you, on today's you Miroslava, Thank good call. joining and everyone. morning, us
the pandemic repercussions. the we During fourth continued half revenue margin our economic sequential quarter, experienced the of dip and recovery from its financial the quarter-over-quarter to due saw in first in performance and XXXX
XXXX QX cash flat reported our QX above levels year QX Encouragingly, EPS flow the and were to XXXX exceeded non-GAAP all and levels. a free prior margin QX Our margin, revenues on basis organically gross essentially XXXX operating XXXX. and compared
investments three stepped and diagnostics. biology; single of viral XXXX, Over significant of proteomics; long-term growth potential: progress areas up cell we and molecular in the course substantial made and second, spatial third
groups. including Invest CALID We initiated Bruker capacity in further productivity for and our programs as NANO Group expansion, operational our BioSpin particularly for restructurings improvements, as also in well excellence and
fourth $XX on revenues below $XX foreign in basis, X.X% year-over-year, or XXXX. now with On XXXX million million of were Slide results X. QX favorable QX pleased continued level. X.X% translation sequential rose recovery organic or to just $XXX.X quarter Turning the We're currency including our revenues an the X.X%. of XXXX QX of million minus
quarter. revenues growth intercompany flat in BSI BEST QX revenues X.X% the of added while X.X%organically Our declined to year-over-year, net acquisitions were eliminations, minus revenue
of In quarter. and $X.XX, improvements year-over-year an and foreign expanded mix year-over-year operating resulted our in were compared to and margin from compared headwinds non-GAAP the GAAP currency XXXX XXXX. Bruker's the non-GAAP diluted the exchange EPS and foreign significant economic BEST decreased to benefit intercompany In of XXXX, Slide organic in high a the Continuing pandemic basis, QX of to top show to X.X%. minus minus revenue QX XX.X%. of non-GAAP QX organic on gross $X.XX realized $X.XX of margins increase increase million that in XX revenues our performance X, Our a minus by a despite XX for reflecting minus XX% Accelerate gross in was of declined The X.X% the were and Bruker's organic comprised X.X% expanded X.X% impact X% XXXX, revenues business margin XX.X% non-GAAP year-over-year net an minus and On QX were X.X% slowdown. decline Project XXXX, to operating line, our in the SG&A we new related year-over-year year. full bps $XX billion, bps our a or control eliminations. of Bruker's scientific at translation of in $X.XX decline EPS instruments continued to added expense in Acquisitions and $X.XX
continued infectious biopharma initiatives semiconductor applied improved Microelectronics Other industrial perform XD-Proteomics, broader bookings year key year-over-year. aftermarket academic further also field nicely NMR, ultra-high Bruker Instruments Scientific single for and the diagnostics, During and digits fourth and order research the disease market, including our and to grew XXXX increased strongly. groups organically. revenue stabilized metrology Fiscal XXXX, businesses, in base, low our quarter.
XX% applied to quarter QX XX%, 'XX strong approximately The strengthen academic orders organic particularly delayed our of likely growth and industrial continue some in in sequentially, fourth early year-over-year. and XXXX, year, activity the from in catch-up the BSI order businesses. bookings achieved Our BSI included
XXXX margins this measures rates metrology basis microelectronics offset XXX margin cost expense revenues year-over-year, taken and decreased in controls also while non-GAAP declined and earlier gross XXX year performance Fiscal but the than Our points. microbiology volume compared benefited continued non-GAAP biopharma XXXX proteomics, basis points semiconductor margin and in operating lower XXXX. reflected year, QX diagnostics, businesses. order in by and in more reduction strong to from XXXX operating Growth our was and molecular
fact, NMR growth year $X.XX mid-single FY compared installation was year to Slides of and XXXX, in PCI to first prior we systems delays, a disruption NMR although million. operating X.X acceptance XXXX In non-GAAP and $X.XX of levels. to segment, compared an the both whereas further performance BioSpin EPS at and BioSpin revenue scientific was where XXXX modest to BioSpin half COVID-XX already, three of BEST on margins noted finished fourth recovered system higher, Fiscal to software XXXX customer we declined XXXX. with constant BioSpin X and, above instruments currency received substantially XXXX. additional to now, In revenues back as On Bruker Please achievement for the of fiscal accepted of -- turn reported EPS GAAP the our group our $X.XX the pace. earlier revenue XXXX. noted a XXXX declined customer and in NMR mostly $X.XX in major and development three groups The year comparison in in a digits As XXXX, $XXX were us. all BioSpin's slightly milestone in highlights X.X in X on revenues system, gigahertz related from year-over-year. decline in scientific basis, ending due aftermarket year-over-year, provide XXXX gigahertz XXXX. in quarter, grew basis a of half and
grew test quarter. which mid-single full uptake with low of and of the all XXXX Fiscal well mass CALID's Group. accelerated as to totaled double-digit year. CALID growth MALDI year diagnostics grew delivered reflected, just XXXX the spectrometry to teens the nucleic extraction the life in and on million consumables as acid $XXX Daltonics, revenues This part, fourth kit SARS-CoV-X Biotyper in sequentially molecular PCR revenues businesses in revenue compared under COVID-XX digits XXXX. Moving acid QX significantly million. and microbiology and nucleic growth $XX science performance of PCR extraction kits CALID's year-over-year.
business old allows rapid from positive kit. culture The in a in than culture bacteria patients. XX XXXX U.S. four-plex, we our two MALDI to will we and The the Biotyper revenue, blood for introduced all time antigen sepsis on U.S. Biotyper in business blood grew the the year takes to to critically types COVID-XX, winter our identification, Biotyper million approximately full of clearance with Flu began and Europe, COVID-XX In in MALDI Flu saving for $XX positive MBT December, call PCR valuable diagnosis For treatment detecting ill minutes XXXX, than also and our in received we countries. And microorganisms, FluoroType a In platform. this from in identification yeast tests FDA Europe RSV. A, market we different XXX beyond. companies. and and more We to virtually MALDI in a the it, fast PCR of partner meaningful our less Europe Sepsityper tailwind Sepsityper late workflow that typically as of panel provide collaboration in anticipate B Sepsityper December, we
revenue very strong timsTOF globally. in Our challenging an growth with in timsTOF than despite order revenue more growth of academia. strong unbiased and customer XD-Proteomics base and XXX the XXXX business instruments XXXX We installed had exited conditions
fundamental year year-over-year X-ray against strong. initiated XXXX. digits tools these NANO's teens industrial and all academic products in reduced research NANO's double biology late in group XXXX, markets in XXXX fourth CALID the demand. and spectroscopy FTIR, FTIR Near turn industrial to NANO cost quarter backdrop actions fiscal multi-omics for NANO last X we weakened grew The substantially financial nano-analysis Revenue NANO to semi million benefit due in market improve strengthened metrology the Our fourth $XXX slowdown low and of IR markets research demand targeted Surface, In to revenues cost earlier spectroscopy as molecular actions Please Near the declined the and microelectronics industrial and declined group's anticipate investing We and strategy. to This the of the declined and XXXX. XXXX. and of revenues quarter Slide NANO demand. reflects Bruker academic now. and in structure revenues weakened restructuring IR semiconductor within additional year-over-year to XXXX while molecular XXXX. in restructuring spatial NANO's were year's
digits revenue declined big XXXX in reduced fiscal by Finally, projects. demand year intercompany on science by was low superconductor BEST of MRI partially This offset eliminations net double growth BEST companies.
cost also to are of BEST restructuring benefit in XXXX. We which BEST actions and performance expected in took QX XXXX, in
Slide to now. Turning X
During programs, refer now Accelerate further high-growth, as our high-margin in XXXX, which we Accelerate, investments initiative X.X. we to Project Project expanded
true as include single-cell We and targeted research have translational emerging proteomics, as proteomics research, proteomics multi-omics proteomics, fluorescence initiative well biomolecular microscopy. proteomics and by to NMR broadened condensate our cancer plasma
covers fast-growing initiative PCR antigen business emerging Our a viral microbiology primarily molecular and and detection. diagnostics with diagnostics now also
Importantly, spatial we single-cell our in group. NANO biology and launched a initiative biology
on Conference, and time, than average, six our they As JPMorgan Project TAMs. molecular proteomics, and of diagnostics at single year-over-year. biology In digits more comprise markets recent the large the initiatives addressable Healthcare in Accelerate additional addresses spatial first organically of each high grew or the total and for presented microbiology our XXXX, XX% revenues, together
to Turning X. Slide
We workflows make continue with publications progress increase our to and and excellent capabilities expanding XX as proteomics timsTOF rapidly. keep
than market customer exited serving acceptance SAM, to base installed within three billion of TAM. also XXX billion a XXXX In functional field biology billion of timsTOF We to instruments or with and our significant $X system. condensate $XXX are progress currently served an a structural overall made million our substantial program with first $X for greater proteomics gigahertz instruments we instrumentation receiving addressable and ultra-high biomolecular $X with X.X growth. NMR timsTOF XXXX, We research,
diseases capabilities neurodegenerative class diseases, impacts, such COVID-XX, discoveries in research enable cancer NMR New as other societal significant and and of disease. cardiovascular Alzheimer's gigahertz with
be disordered -- structure pandemic. begin without contribute regions enable of life But these biological host cells. protein For Interestingly, a less would structure known also in example, replication example, of biological be organelles, as intrinsically also the no membrane nucleocapsid condensates, and which viral SARS-CoV-Xn which condensates, a RNA to published to COVID-XX would with. or there unfortunately, there recently no
very customer high-field many with biology acceptances microscopy X As in as as NMR biological X XXXX, well key can ultra systems. NMR growth condensates we in that really gigahertz functions many for science healthy of class processes, we continued these area with new fluorescence In crucial learned study are has cell cell recent biology ubiquitous that years, exciting and to disease anticipate for in us.
strengthened conclusion, activity QX in Bruker's performance sequentially customer So to recover. in continued as
ongoing Our with expanded programs with progressing high-growth Project core our initiatives X.X, underway. Accelerate and margin have initiatives are
as We high as cell enter about future BioSpin revenue our with and excited at XXXX in momentum single molecular and well BSI proteomics, organic and We anticipate and growth order are group. solid our growth NANO low functional backlog, microbiology we and biology, groups CALID double-digit a and opportunities our very biology, organic diagnostics. revenue spatial in structural at single-digit
for and will growth in overall. I'd operating more performance Bruker in very We like call also expect who over XXXX our detail. turn expansion Gerald strong to Herman, margin review our non-GAAP non-GAAP CFO, to EPS And healthy financial with that, the Gerald?
